Skip to main content
. 2018 Oct 23;17(1):221–229. doi: 10.3892/ol.2018.9607

Figure 1.

Figure 1.

MIR31HG has higher expression in NSCLC tissues and cells. (A) RT-qPCR analysis of MIR31HG expression in 88 cases of NSCLC tissues and adjacent normal tissues. The expression of MIR31HG was normalized to GAPDH expression. (B) Kaplan-Meier survival analysis was performed to detect the association between MIR31HG expression and clinicopathologic parameters in 88 cases of NSCLC patients. (C) RT-qPCR analysis of MIR31HG expression in the three human NSCLC cell lines A549, H1299 and NCIH460 and the normal human bronchial epithelial cell line 16HBE. The expression of MIR31HG was normalized to GAPDH expression. RT-qPCR analysis of MIR31HG expression following transfection with si-NC, si-MIR31HG-1, si-MIR31HG-2 into (D) NCIH460 or (E) A549 cells, The expression of MIR31HG was normalized to GAPDH expression. **P<0.05 vs. non-tumor, 16HBE, si-NC. Every independent experiment was performed three times. NSCLC, non-small cell lung cancer; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; si, small interfering; NC, negative control.